Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ?
Idiopathic pulmonary fibrosis
Interstitial lung disease
Obstructive lung disease
Progressive fibrosing ILD
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
11 Apr 2022
11 Apr 2022
Historique:
received:
09
11
2021
accepted:
24
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Patients suffering from combined obstructive and interstitial lung disease (O-ILD) represent a pathological entity which still has to be well clinically described. The aim of this descriptive and explorative study was to describe the phenotype and functional characteristics of a cohort of patients suffering from functional obstruction in a population of ILD patients in order to raise the need of dedicated prospective observational studies and the evaluation of the impact of anti-fibrotic therapies. The current authors conducted a retrospective study including 557 ILD patients, with either obstructive (O-ILD, n = 82) or non-obstructive (non O-ILD, n = 475) pattern. Patients included were mainly males (54%) with a mean age of 62 years. Patients with O-ILD exhibited a characteristic functional profile with reduced percent predicted forced expired volume in 1 s (FEV1) [65% (53-77) vs 83% (71-96), p < 0.00001], small airway involvement assessed by maximum expiratory flow (MEF) 25/75 [29% (20-41) vs 81% (64-108), p < 0.00001], reduced sGaw [60% (42-75) vs 87% (59-119), p < 0.01] and sub-normal functional residual capacity (FRC) [113% (93-134) vs 92% (75-109), p < 0.00001] with no impaired of carbon monoxide diffusing capacity of the lung (DLCO) compared to those without obstruction. Total lung capacity (TLC) was increased in O-ILD patients [93% (82-107) vs 79% (69-91), p < 0.00001]. Of interest, DLCO sharply dropped in O-ILD patients over a 5-year follow-up. We did not identify a significant increase in mortality in patients with O-ILD. Interestingly, the global mortality was increased in the specific sub-group of patients with O-ILD and no progressive fibrosing ILD phenotype and in those with connective tissue disease associated ILD especially in case of rheumatoid arthritis. The authors individualized a specific functional-based pattern of ILD patients with obstructive lung disease, who are at risk of increased mortality and rapid DLCO decline over time. As classically those patients are excluded from clinical trials, a dedicated prospective study would be of interest in order to define more precisely treatment response of those patients.
Sections du résumé
BACKGROUND
BACKGROUND
Patients suffering from combined obstructive and interstitial lung disease (O-ILD) represent a pathological entity which still has to be well clinically described. The aim of this descriptive and explorative study was to describe the phenotype and functional characteristics of a cohort of patients suffering from functional obstruction in a population of ILD patients in order to raise the need of dedicated prospective observational studies and the evaluation of the impact of anti-fibrotic therapies.
METHODS
METHODS
The current authors conducted a retrospective study including 557 ILD patients, with either obstructive (O-ILD, n = 82) or non-obstructive (non O-ILD, n = 475) pattern. Patients included were mainly males (54%) with a mean age of 62 years.
RESULTS
RESULTS
Patients with O-ILD exhibited a characteristic functional profile with reduced percent predicted forced expired volume in 1 s (FEV1) [65% (53-77) vs 83% (71-96), p < 0.00001], small airway involvement assessed by maximum expiratory flow (MEF) 25/75 [29% (20-41) vs 81% (64-108), p < 0.00001], reduced sGaw [60% (42-75) vs 87% (59-119), p < 0.01] and sub-normal functional residual capacity (FRC) [113% (93-134) vs 92% (75-109), p < 0.00001] with no impaired of carbon monoxide diffusing capacity of the lung (DLCO) compared to those without obstruction. Total lung capacity (TLC) was increased in O-ILD patients [93% (82-107) vs 79% (69-91), p < 0.00001]. Of interest, DLCO sharply dropped in O-ILD patients over a 5-year follow-up. We did not identify a significant increase in mortality in patients with O-ILD. Interestingly, the global mortality was increased in the specific sub-group of patients with O-ILD and no progressive fibrosing ILD phenotype and in those with connective tissue disease associated ILD especially in case of rheumatoid arthritis.
CONCLUSIONS
CONCLUSIONS
The authors individualized a specific functional-based pattern of ILD patients with obstructive lung disease, who are at risk of increased mortality and rapid DLCO decline over time. As classically those patients are excluded from clinical trials, a dedicated prospective study would be of interest in order to define more precisely treatment response of those patients.
Identifiants
pubmed: 35410260
doi: 10.1186/s12931-022-02006-9
pii: 10.1186/s12931-022-02006-9
pmc: PMC8996531
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
89Informations de copyright
© 2022. The Author(s).
Références
Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76
pubmed: 11316667
J Pers Med. 2021 Jun 25;11(7):
pubmed: 34202096
Chest. 1997 Mar;111(3):813-6
pubmed: 9118726
Acta Clin Belg. 2018 Apr;73(2):139-143
pubmed: 29125071
Thorax. 2006 Nov;61(11):980-5
pubmed: 16844727
Am J Surg Pathol. 1994 Feb;18(2):136-47
pubmed: 8291652
Front Immunol. 2021 Jun 07;12:684699
pubmed: 34163483
Proc Am Thorac Soc. 2009 Sep 15;6(6):524-6
pubmed: 19741261
Ann Rheum Dis. 1997 Aug;56(8):463-9
pubmed: 9306868
ERJ Open Res. 2022 Jan 24;8(1):
pubmed: 35083316
Am J Respir Crit Care Med. 1996 Feb;153(2):861-5
pubmed: 8564146
Curr Opin Pulm Med. 2000 Sep;6(5):399-403
pubmed: 10958229
J Med Chem. 2017 Jan 26;60(2):527-553
pubmed: 28122457
Chest. 2020 Aug;158(2):646-659
pubmed: 32268131
Chest. 2012 Jan;141(1):222-231
pubmed: 22215830
Am J Respir Crit Care Med. 2020 Aug 1;202(3):e36-e69
pubmed: 32706311
Am J Respir Crit Care Med. 1997 Jan;155(1):242-8
pubmed: 9001319
Respir Res. 2020 Jun 30;21(1):164
pubmed: 32605574
Radiology. 1998 Dec;209(3):697-704
pubmed: 9844661
Mayo Clin Proc. 1978 Dec;53(12):788-91
pubmed: 732355
Respirology. 2016 Feb;21(2):259-68
pubmed: 26564810
Respir Med. 2017 Aug;129:24-30
pubmed: 28732832
Eur Respir J. 2001 Jan;17(1):122-32
pubmed: 11307741
Respir Med. 2021 Jun;182:106420
pubmed: 33894441
Int J Chron Obstruct Pulmon Dis. 2014 Jul 29;9:805-11
pubmed: 25114520
Expert Rev Respir Med. 2013 Feb;7(1):19-31; quiz 32
pubmed: 23362797
Thorax. 2020 Oct;75(10):870-881
pubmed: 32759383
Am J Respir Crit Care Med. 1994 Oct;150(4):967-72
pubmed: 7921471
Arthritis Res Ther. 2010;12(4):213
pubmed: 20735863
Lancet Respir Med. 2020 May;8(5):453-460
pubmed: 32145830
Med Res Rev. 2022 Jan;42(1):426-440
pubmed: 34309893
Clin Rev Allergy Immunol. 2003 Oct;25(2):115-29
pubmed: 14573880
Eur Respir Rev. 2015 Mar;24(135):1-16
pubmed: 25726549
Clin Chest Med. 2008 Sep;29(3):365-77, vii
pubmed: 18539232
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Sarcoidosis Vasc Diffuse Lung Dis. 2002 Mar;19(1):10-7
pubmed: 12002379
Thorax. 2008 Sep;63 Suppl 5:v1-58
pubmed: 18757459
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
Am J Respir Crit Care Med. 2021 Feb 15;203(4):414-423
pubmed: 33211970
N Engl J Med. 1985 Jan 17;312(3):152-8
pubmed: 3965933